

The Future of Combination Therapies of Insulin with a Glucagon-like Peptide-1 Receptor Agonists in Type 2 Diabetes – Is it Advantageous?

Baptist Gallwitz

Professor of Medicine, Department of Medicine IV, Eberhard Karls University, Tübingen, Germany

Citation: *European Endocrinology*, 2015;11(1):xii[online only]

Erratum to: *European Endocrinology*, 2014;10(2):98–9

In order to comply with the latest recommendations outlined by ICMJE the publisher would like to make the following amendments to the Disclosure section of the above-mentioned paper: No funding was received for the publication of this article.